Researchers retract narcolepsy study linked to Glaxo's Pandemrix

Scientists thought they may have been on to something as far as deciphering the link between GlaxoSmithKline's ($GSK) pandemic swine flu vaccine and narcolepsy. But now, unable to replicate their findings, they've retracted the study. Evidence of an increased risk of narcolepsy in children who had received GSK's vaccine mounted last year, with a study in the British Medical Journal, for one, adding to data from Finland and France. Report | More

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.